Clinical results for Episealer® accepted for presentation at the 38[th] AGA Congress
Episurf Medical (Nasdaq: EPIS B) today announces that an abstract with results from follow-up of Episealer® Knee implant patients will be presented by Priv.-Doz. Dr. med. Clemens Kösters at the 38th annual AGA Congress in Innsbruck, Austria, which will take place on September 9-11.
The abstract with the title “Good clinical results after implantation of single vs. multiple patient-specific mini-implants in therapy-resistant focal femoral (osteo-) chondral lesions in middle-aged patients” presents the clinical outcome for patients who received multiple Episealer® implants compared with the results for patients who received one Episealer® implant for treatment of focal chondral and osteochondral defects in the knee.
“Our results astonishingly demonstrated that the clinical results of patients with 2 or 3 Episealer® implants were just as good as those with 1 Episealer® implant. Furthermore, both groups did not show any complications” says Priv.-Doz. Dr. med. Clemens Kösters.
“The use of 2-3 implants has become relatively frequent among some of the Episealer® surgeons, but publications of clinical follow-up data are limited. We look forward to seeing the results from this independent group of authors presented at this important congress” says Pål Ryfors, CEO Episurf Medical.
AGA-Society for Arthroscopy and Joint-Surgery is a German speaking scientific organisation and one of Europe’s largest professional organisations within arthroscopy and joint-surgery.
For more information, please contact:
Pål Ryfors, CEO, Episurf Medical
Tel:+46 (0) 709 62 36 69
Email: pal.ryfors@episurf.com
About Episurf Medical
Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and individualised treatment alternatives. Episurf Medical’s Episealer® individualised implants and Epiguide® surgical drill guides are developed for treating localised cartilage injury in joints. Episurf Medical’s μiFidelity® system enables implants to be cost-efficiently tailored to each individual’s unique injury for the optimal fit and minimal intervention. Episurf Medical’s head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company’s website: www.episurf.com.
Tags: